Combining a unique and patented dry-fog diffusion technology with ultra-high performance hydrogen peroxide-based disinfectant, the innovative STERINIS® process meets all the requirements of the biocide directive CE 98/8. It guarantees the extensive eradication of pathogenic microorganisms by disinfecting all surfaces, even those which are inaccessible or hidden. It thus makes it possible to guard against contaminations and infections, especially nosocomial infections. It unites effectiveness with safety and a considerable reduction in disinfection costs. In the past year the system’s developer, Gloster Santé Europe, doubled its international distribution network.
STERINIS® integrates a one-of-its-kind traceability system which enables all disinfecting operations to be recorded with a data log available via the USB port. Its automatic monitoring and simple operating systems make it perfectly adapted for use by non-specialized personnel. It also allows for savings to be generated. This disinfection technology requires no human presence and shortens the amount of downtime for rooms undergoing treatment. Almost instantly, this process has made its mark as an indispensable tool in global hygiene protocols.
The Canon® Group (Canon Brittany), which has an industrial partnership agreement with Gloster Santé Europe, has manufactured STERINIS® since November 2004. The experience and worldwide organization of the Canon® Group guarantee the products a very high level of quality and logistics optimization. Currently distributed in 17 countries with 14 more awaiting approval, it is used by renowned hospitals, clinics, and laboratories across Europe, North Africa, and the Middle East for prevention and treatment purposes. This success follows its international scientific recognition, a coherent marketing policy, as well as perfect cooperation between Gloster Santé Europe and its distributors.
The STERINIS® disinfection process has convinced a very large number of decision-makers in the fields of hospital care, pharmaceuticals, and food business. The results of the tests carried out under both laboratory conditions and actual hospital usage conditions (operating theatre suites, recovery rooms, infectious diseases rooms, dental surgeries, etc.) in France and abroad (Norway, Denmark, Holland, Ireland, Taiwan, Turkey, etc.) cannot be disputed. STERINIS® is one of the highest performing disinfection processes on the market.
STERINIS
® complies with the NF harmonized standards as well as the CE directives, among which the AFNOR standard NF T 72-281 and the biocide directive CE 98/8. Moreover, Gloster Santé Europe has ISO 9001:2000 and ISO 13485:2003 certification awarded by SGS Yarsley, a UKAS accredited body. STERINIS
® is neither corrosive nor toxic and is 99.99% biodegradable. All assessment reports can be downloaded from
www.sterinis.com.
Gloster Santé Europe will be presenting STERINIS® at the following trade shows in 2006: ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) in Nice from April 1 to 4 (Acropolis Congress Centre); Hôpital Expo – Intermedica in Paris (Porte de Versailles) from May 16 to 19; AFSTAL in Bordeaux (Palais des Congrès) from May 31 to June 2; SIPEC (Pharmaceuticals and Cosmetics Industries Trade Fair) in Orléans (Palais des Congrès) from September 12 to 14; and MEDICA 2006 in Düsseldorf, Germany, in November.
For further information, please contact:
GLOSTER SANTE EUROPE
Frédéric Pradelle
31672 Labège Cedex
France
Tel: +33 (0) 5 62 88 42 22